FNY Investment Advisers LLC Takes $54,000 Position in Cibus, Inc. $CBUS

FNY Investment Advisers LLC purchased a new stake in Cibus, Inc. (NASDAQ:CBUS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 39,146 shares of the company’s stock, valued at approximately $54,000.

A number of other large investors also recently made changes to their positions in the stock. Armistice Capital LLC acquired a new position in shares of Cibus in the 1st quarter valued at $3,643,000. Certior Financial Group LLC lifted its stake in shares of Cibus by 72.2% in the 1st quarter. Certior Financial Group LLC now owns 146,348 shares of the company’s stock valued at $274,000 after purchasing an additional 61,363 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Cibus by 32.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 55,142 shares of the company’s stock valued at $103,000 after purchasing an additional 13,583 shares during the period. AQR Capital Management LLC acquired a new position in shares of Cibus in the 1st quarter valued at $73,000. Finally, Nuveen LLC acquired a new position in shares of Cibus in the 1st quarter valued at $71,000. Institutional investors and hedge funds own 33.81% of the company’s stock.

Cibus Stock Up 9.7%

CBUS opened at $1.58 on Friday. Cibus, Inc. has a 12 month low of $1.20 and a 12 month high of $6.10. The company has a fifty day simple moving average of $1.40 and a 200 day simple moving average of $1.71. The stock has a market cap of $85.70 million, a P/E ratio of -0.15 and a beta of 1.72.

Cibus (NASDAQ:CBUS) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.61) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.08. Cibus had a negative net margin of 5,681.55% and a negative return on equity of 83.67%. The business had revenue of $0.93 million during the quarter, compared to analysts’ expectations of $1.15 million. On average, equities research analysts expect that Cibus, Inc. will post -2.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cibus in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $21.25.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.